BIO Should Use Political Clout Carefully, Outgoing President Feldbaum Urges
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotechnology industry should reserve its political "hammer" for key policy issues, such as intellectual property rights, unreasonable regulation and price controls, BIO's Feldbaum says in farewell address to trade association. BIO holds a formidable weapon, but "don't use it as a sledgehammer," Feldbaum advises.
You may also be interested in...
PhRMA "Is Going To Be Different," Chairman White Pledges; Trade Group Must Be "More Than Advocacy"
Abbott CEO sketches out ambitious agenda for trade association in the coming year, with proposals to simplify patient assistance programs, set standards for DTC and work to educate consumers about pricing. To underscore the transition, outgoing Chairman Bob Essner (Wyeth) chooses a new metaphor: passing the sledgehammer, not the gavel.
BIO Will Have New President By End Of Year; Feldbaum Stepping Down
BIO President Carl Feldbaum is stepping down after 11 years. His successor will face emerging debate on "generic" biologics and implementation of the Medicare law.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability